摘要
目的探讨全身低剂量CT检查在多发性骨髓瘤病人诊断及分期中的应用价值。方法收集2016年10月至2018年10月保定市第一中心医院血液科58例经临床病理证实的多发性骨髓瘤病人的全身低剂量CT检查的影像学资料,以此进行Durie/Salmon plus分期,同时进行临床ISS分期,比较两者在溶骨性病灶的差异性和一致性。结果58例多发性骨髓瘤病人共发现558处溶骨性病灶,其中Durie/Salmon plus分期:Ⅰ期12例,Ⅱ期32例,Ⅲ期14例;临床ISS分期:Ⅰ期18例,Ⅱ期21例,Ⅲ期19例。两种分期相比差异无统计学意义(χ^2=4.241,P=0.120),Kappa值为0.423,具有中等程度的一致性。结论Durie/Salmon plus分期和ISS分期之间差异无统计学意义,全身低剂量CT检查在多发性骨髓瘤诊断及分期中有良好的应用价值。
Objective To investigate the value of whole⁃body low⁃dose CT in the diagnosis and staging of patients with multiple myeloma.Methods The imaging data of 58 patients with multiple myeloma confirmed by clinical pathology in the Department of Hematology of The First Central Hospital of Baoding from October 2016 to October 2018 were collected and separated by the Durie/Salmon plus staging and the clinical ISS staging.The difference and consistency between them in osteolytic lesions were compared.Results A total of 558 osteolytic lesions were found in the 58 patients with multiple myeloma,including Durie/Salmon plus stageⅠ(n=12),stageⅡ(n=32)and stageⅢ(n=14),and clinical ISS stage:stageⅠ(n=18),stageⅡ(n=21)and stageⅢ(n=19).There was no significant difference between the two stages(χ^2=4.241,P=0.120),and the Kappa value was 0.423,which was moderately consistent.Conclusion There is no significant difference between Durie/Salmon plus staging and ISS staging.The whole⁃body low⁃dose computed tomography has good application value in the diagnosis and staging of multiple myeloma.
作者
章双林
刘冲
陈陽
王淑梅
ZHANG Shuanglin;LIU Chong;CHEN Yang;WANG Shumei(Graduate School of Chengde Medical College,Chengde,Hebei 067000,China;CT/MR Room,The First Central Hospital of Baoding,Baoding,Hebei 071000,China)
出处
《安徽医药》
CAS
2020年第3期477-480,共4页
Anhui Medical and Pharmaceutical Journal
基金
河北省教育厅在读研究生创新能力培养资助项目(CXZZSS2017142)
